• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BOSTON SCIENTIFIC CORPORATION TRIA SOFT; STENT, URETERAL

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BOSTON SCIENTIFIC CORPORATION TRIA SOFT; STENT, URETERAL Back to Search Results
Model Number M0061903220
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Unspecified Infection (1930); Sepsis (2067); Swelling/ Edema (4577); Insufficient Information (4580)
Event Date 02/21/2022
Event Type  Injury  
Manufacturer Narrative
(b)(6).Study: u0652 double-j registry clinical study.(b)(4).The complainant indicated that the device was disposed and will not be returned for evaluation; therefore, a problem analysis of the complaint device could not be completed.If any further relevant information is identified, a supplemental medwatch will be filed.
 
Event Description
It was reported to boston scientific corporation that a tria soft ureteral stent was implanted during a laser lithotripsy procedure in the right ureter on (b)(6) 2022 as part of the u0652 double-j registry clinical study.On (b)(6) 2022 the stent was successfully implanted and the patient was prescribed alpha blocker and nsaids at discharge.It was reported the stent was removed successfully on (b)(6) 2019 and pain control was not required.On (b)(6) 2022 following stent removal, it was reported that the patient was brought to the emergency room and had ureteral interventional procedure stent insertion (reimplantation) on the right side and was given a medication of piperacillin and tazobactam.On (b)(6) 2022 the event was considered resolved.
 
Manufacturer Narrative
Block e1: initial reporter state: (b)(6).Block g3: study: u0652 double-j registry clinical study.Block h6: patient impact code f2303 captures the reportable event of medication required.Patient impact code f08 captures the reportable event of hospitalization.Block h11: block b5 have been updated based on additional information received on august 30, 2022.
 
Event Description
It was reported to boston scientific corporation that a tria soft ureteral stent was implanted during a laser lithotripsy procedure in the right ureter on (b)(6) 2022 as part of the u0652 double-j registry clinical study.On (b)(6) 2022 the stent was successfully implanted and the patient was prescribed alpha blocker and nsaids at discharge.It was reported the stent was removed successfully on (b)(6) 2022 and pain control was not required.On february 21, 2022, following stent removal, it was reported that the patient was brought to the emergency room and had ureteral interventional procedure stent insertion (reimplantation) on the right side and was reported to have a septic stone and was given a medication of piperacillin and tazobactam.On february 23, 2022 the event was considered resolved.
 
Manufacturer Narrative
E1: initial reporter state: bc v5z 1m9 g3: study: u0652 double-j registry clinical study.H6: patient impact code f2303 captures the reportable event of medication required.Patient impact code f08 captures the reportable event of hospitalization.Patient code e0306 captures the reportable event of sepsis.Patient code e1906 captures the reportable event of unspecified infection.H11: block b5 have been updated based on additional information received on august 30, 2022.Block b5 have been updated based on additional information received on september 23, 2022.Updated block h6 for patient code.
 
Event Description
It was reported to boston scientific corporation that a tria soft ureteral stent was implanted during a laser lithotripsy procedure in the right ureter on (b)(6) 2022 as part of the u0652 double-j registry clinical study.On (b)(6) 2022 the stent was successfully implanted and the patient was prescribed alpha blocker and nsaids at discharge.It was reported the stent was removed successfully on (b)(6) 2022 and pain control was not required.On (b)(6) 2022, following stent removal, it was reported that the patient was brought to the emergency room and had ureteral interventional procedure stent insertion (reimplantation) on the right side and was reported to have a septic stone and was given a medication of piperacillin and tazobactam.On (b)(6) 2022 the event was considered resolved.Additional information received on september 19, 2022 reported that the patient experienced a septic kidney stone, sepsis or infection, requiring antibiotics.
 
Event Description
It was reported to boston scientific corporation that a tria soft ureteral stent was implanted during a laser lithotripsy procedure in the right ureter on february 14, 2022 as part of the u0652 double-j registry clinical study.On (b)(6) 2022 the stent was successfully implanted and the patient was prescribed alpha blocker and nsaids at discharge.It was reported the stent was removed successfully on (b)(6) 2022 and pain control was not required.On (b)(6) 2022, following stent removal, it was reported that the patient was brought to the emergency room and had ureteral interventional procedure stent insertion (reimplantation) on the right side and was reported to have a septic stone and was given a medication of piperacillin and tazobactam.On (b)(6) 2022 the event was considered resolved.Additional information received on september 19, 2022 reported that the patient experienced a septic kidney stone, sepsis or infection, requiring antibiotics.
 
Manufacturer Narrative
Block e1: initial reporter state: (b)(6).Block g3: study: u0652 double-j registry clinical study.Block h6: patient impact code f2303 captures the reportable event of medication required.Patient impact code f08 captures the reportable event of hospitalization.Patient code e0306 captures the reportable event of sepsis.Patient code e1906 captures the reportable event of unspecified infection.Block h11: block b6 has been corrected.
 
Manufacturer Narrative
Block g3: study: (b)(4) double-j registry clinical study.Block h6: imdrf impact code f2303 captures the reportable event of medication required.Imdrf impact code f08 captures the reportable event of hospitalization.Imdrf patient code e0306 captures the reportable event of sepsis.Imdrf patient code e1906 captures the reportable event of unspecified infection.Imdrf patient code e2338 captures the reportable event of swelling.Block h11: block b5 have h6 have been updated based on additional information received on february 27, 2023.
 
Event Description
It was reported that a tria soft ureteral stent was implanted during a laser lithotripsy procedure in the right ureter on (b)(6) 2022, as part of the (b)(4) double-j registry clinical study.On (b)(6) 2022, the stent was successfully implanted, and the patient was prescribed alpha blocker and nsaids at discharge.It was reported the stent was removed successfully on (b)(6) 2022, and pain control was not required.On (b)(6) 2022, following stent removal, it was reported that the patient was brought to the emergency room and had ureteral interventional procedure stent insertion (reimplantation) on the right side and was reported to have a septic stone and was given a medication of piperacillin and tazobactam.The patient was hospitalized (b)(6) 2022.The onset date was on february 21, 2022, with an onset latency of 7 days and with a stop date of february 23, 2022.There was no reported action taken and the event outcome was resolved.Additional information received on september 19, 2022, reported that the patient experienced a septic kidney stone, sepsis or infection, requiring antibiotics.Additional information received on january 19, 2023, reported another device lot number 24951653, that was used in the left ureter.The stent was successfully implanted, and procedure was performed without any complication.Additional information received on february 27, 2023, reported a new event of hydronephrosis with a severity of moderate.The onset date was on (b)(6) 2022, with an onset latency of 7 days and with a stop date of (b)(6) 2022.The clavien-dindo classification was noted as grade iiib.There was no reported action taken and the event was resolved.
 
Manufacturer Narrative
Block g3: study: u0652 double-j registry clinical study.Block h6: patient impact code f2303 captures the reportable event of medication required.Patient impact code f08 captures the reportable event of hospitalization.Patient code e0306 captures the reportable event of sepsis.Patient code e1906 captures the reportable event of unspecified infection.Block h11: block e1 has been corrected.Block b5 has been corrected.Block b5 has been updated based on additional information received on january 19, 2023.
 
Event Description
It was reported to boston scientific corporation that a tria soft ureteral stent was implanted during a laser lithotripsy procedure in the right ureter on (b)(6)2022, as part of the u0652 double-j registry clinical study.On (b)(6) 2022, the stent was successfully implanted, and the patient was prescribed alpha blocker and nsaids at discharge.It was reported the stent was removed successfully on (b)(6), 2022, and pain control was not required.On (b)(6)2022, following stent removal, it was reported that the patient was brought to the emergency room and had ureteral interventional procedure stent insertion (reimplantation) on the right side and was reported to have a septic stone and was given a medication of piperacillin and tazobactam.The patient was hospitalized from (b)(6) 2022, to (b)(6) 2022.On (b)(6) 2022, the event was considered resolved.Additional information received on (b)(6)2022, reported that the patient experienced a septic kidney stone, sepsis or infection, requiring antibiotics.Additional information received on (b)(6) 2023, reported another device lot number 24951653, that was used in the left ureter.The stent was successfully implanted, and procedure was performed without any complication.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
TRIA SOFT
Type of Device
STENT, URETERAL
Manufacturer (Section D)
BOSTON SCIENTIFIC CORPORATION
300 boston scientific way
marlborough MA 01752
Manufacturer (Section G)
BOSTON SCIENTIFIC CORPORATION
2546 calle primera
alajuela
CS  
Manufacturer Contact
carole morley
300 boston scientific way
marlborough, MA 01752
5086834015
MDR Report Key14983085
MDR Text Key295673372
Report Number3005099803-2022-03581
Device Sequence Number1
Product Code FAD
UDI-Device Identifier08714729959892
UDI-Public08714729959892
Combination Product (y/n)N
Reporter Country CodeCA
PMA/PMN Number
K191609
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Other,Foreign,Health Professional,Company Representative
Reporter Occupation Physician
Type of Report Initial,Followup,Followup,Followup,Followup
Report Date 03/20/2023
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Model NumberM0061903220
Device Catalogue Number1983-02
Device Lot Number0027999242
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Initial Date Manufacturer Received 06/15/2022
Initial Date FDA Received07/11/2022
Supplement Dates Manufacturer Received08/30/2022
09/19/2022
10/24/2022
01/19/2023
02/27/2023
Supplement Dates FDA Received09/20/2022
10/14/2022
11/16/2022
02/13/2023
03/20/2023
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Date Device Manufactured09/10/2021
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention; Hospitalization;
Patient Age58 YR
Patient SexFemale
-
-